4.4 Article

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19

Myron J. Levin et al.

Summary: A single dose of AZD7442 showed efficacy in preventing Covid-19 without evident safety concerns. The study suggests that AZD7442 may provide potential protection for individuals who have an inadequate response to vaccination or an increased risk of exposure.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Letter Critical Care Medicine

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants

Sara Y. Tartof et al.

LANCET RESPIRATORY MEDICINE (2022)

Letter Medicine, General & Internal

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants

Emi Takashita et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Public, Environmental & Occupational Health

Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022

Jason Robert C. Singson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Article Medicine, General & Internal

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

M. G. Thompson et al.

Summary: A study with a test-negative design analyzed 41,552 admissions to 187 hospitals and 21,522 visits to 221 EDs or urgent care clinics. The mRNA-based vaccines (>= 14 days after the second dose) were highly effective against SARS-CoV-2 infection leading to hospitalization (89%), ICU admission (90%), or an urgent care visit (91%).

NEW ENGLAND JOURNAL OF MEDICINE (2021)